Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study) 7. Juni 2021 Zeuschner P., Hölters S., Stöckle M., Seliger B., Mueller A., Bachmann H. S., Grünwald V., Christoph D.C., Stenzl A., Grimm M.-O., Brüning F., Goebell P. J., Augustin M., Roos F., Harde J., Benz-Rüd I., Staehler M., Junker K. Abstract Download Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos,… Weiterlesen First line therapy with Lenalidomide and Dexamethasone in transplant-ineligible patients with multiple myeloma: Final results of the observational study FIRST-NIS. Nückel H., Behlendorf T., Schulz H., Schulze M., Söling U., Bürkle D., Koenigsmann M., Medinger T., Dechow T., Schardt C., Vannier C., Niemeier B., Schmidt… Weiterlesen